Imugene (ASX; IMU) is an immuno-oncology focused biopharmaceutical company developing PD-1, HER-1, HER-2, HER-3, VEGF, IGF-1R cancer immunotherapies. Our mission is to build a pipeline of B-cell peptide cancer vaccines and therapeutics.
View MD/CEO Leslie Chong being interviewed by Commsec's Tom Piotrowski 13 June 2018 (click here).
Our lead product is HER-Vaxx, a proprietary therapeutic cancer immunotherapy that stimulates a polyclonal antibody response to HER-2/neu, the same biomarker targeted by the $US6.9 billion per annum drug Herceptin®. Imugene is also developing a B cell vaccine, KEY-Vaxx, targeting PD-1 and specifically the same PD-1 binding region of Keytruda®.
We also added by way of an announcement on 7 June 2018, an exclusive, world-wide licence to the entire body of cancer vaccine work and intellectual property developed by Professor Pravin T. P. Kaumaya of The Ohio State University Wexner Medical Center and The Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and The Mayo Clinic. Included in the pipeline is a PD-1 targeting cancer vaccine, KEY-Vaxx, that has shown robust inhibition of tumour growth in validated pre-clinical animal models.
Click here to view latest Imugene Fact Sheet
Click here to view video that introduces HER-Vaxx and explains how it works
Click here to view Imugene's current share price
Click here to view Leslie Chong interview with Medicalresearch.com "Imugene Building Pipeline of B Cell Peptide Cancer Vaccines".
Click here to read "What's Hot & What's Not in Immuno-Oncology Licensing. Dr Axel Hoos is interviewed as part of an expert panel.
Imugene’s corporate headquarters are located in Melbourne and Sydney, Australia with scientific teams in Vienna Austria and Columbus Ohio.